Hapten Sciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Hapten Sciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04853823
A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Hapten Sciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02700373
- Locations
- 🇺🇸
Clinical Research Solutions, Franklin, Tennessee, United States
News
No news found